X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse GSK Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GSK PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
ADCOCK INGRAM
Jun-14
GSK PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs3,838365-   
Low Rs2,637264-   
Sales per share (Unadj.) Rs354.2108.7-  
Earnings per share (Unadj.) Rs39.8-27.4-  
Cash flow per share (Unadj.) Rs42.9-22.7-  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.985.3-  
Shares outstanding (eoy) m84.70168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.12.9 315.9%   
Avg P/E ratio x81.4-11.5 -709.1%  
P/CF ratio (eoy) x75.5-13.9 -545.0%  
Price / Book Value ratio x13.73.7 370.7%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,21653,081 516.6%   
No. of employees `0004.74.3 109.4%   
Total wages/salary Rs m4,8303,331 145.0%   
Avg. sales/employee Rs Th6,387.04,273.4 149.5%   
Avg. wages/employee Rs Th1,028.3776.0 132.5%   
Avg. net profit/employee Rs Th717.1-1,076.8 -66.6%   
INCOME DATA
Net Sales Rs m30,00018,346 163.5%  
Other income Rs m728128 566.8%   
Total revenues Rs m30,72818,474 166.3%   
Gross profit Rs m4,190-3,179 -131.8%  
Depreciation Rs m263792 33.2%   
Interest Rs m0497 0.0%   
Profit before tax Rs m4,655-4,339 -107.3%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744271 643.2%   
Profit after tax Rs m3,368-4,623 -72.9%  
Gross profit margin %14.0-17.3 -80.6%  
Effective tax rate %37.5-6.2 -599.6%   
Net profit margin %11.2-25.2 -44.6%  
BALANCE SHEET DATA
Current assets Rs m16,74213,437 124.6%   
Current liabilities Rs m7,2027,560 95.3%   
Net working cap to sales %31.832.0 99.3%  
Current ratio x2.31.8 130.8%  
Inventory Days Days52111 46.7%  
Debtors Days Days21124 16.8%  
Net fixed assets Rs m8,6357,832 110.3%   
Share capital Rs m84785 994.4%   
"Free" reserves Rs m19,2220-   
Net worth Rs m20,06914,399 139.4%   
Long term debt Rs m105,060 0.2%   
Total assets Rs m30,03827,201 110.4%  
Interest coverage xNM-7.7-  
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x1.00.7 148.1%   
Return on assets %11.2-15.2 -73.9%  
Return on equity %16.8-32.1 -52.3%  
Return on capital %25.5-19.8 -128.5%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-6,6650-   
CASH FLOW
From Operations Rs m2,3601,566 150.7%  
From Investments Rs m3,008-481 -625.6%  
From Financial Activity Rs m-5,1084,592 -111.2%  
Net Cashflow Rs m2605,678 4.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.04 Rs / ZAR

Compare GSK PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare GSK PHARMA With: PLETHICO PHARMA  LUPIN LTD  FDC LTD.  ORCHID PHARMA LTD  IPCA LABS  



Today's Market

Sensex Trades on a Volatile Note; Idea Cellular Plunges 6%(12:30 pm)

After opening the day flat share markets in India are trading on a dull note and are presently trading marginally below the dotted line.

Related Views On News

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jun 25, 2018 01:01 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - STERLING BIOTECH COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS